Srikanth Ambati

2.3k total citations
62 papers, 538 citations indexed

About

Srikanth Ambati is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Srikanth Ambati has authored 62 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 35 papers in Pathology and Forensic Medicine and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Srikanth Ambati's work include Lymphoma Diagnosis and Treatment (35 papers), CAR-T cell therapy research (31 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Srikanth Ambati is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), CAR-T cell therapy research (31 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Srikanth Ambati collaborates with scholars based in United States, Spain and South Korea. Srikanth Ambati's co-authors include Alessandro Marturano-Kruik, Malcolm A.S. Moore, Aránzazu Villasante, Gordana Vunjak‐Novakovic, Aafia Chaudhry, Min Zhu, Paul A. Meyers, Emily K. Slotkin, Dina M. Flink and Hesam Parsa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biomaterials.

In The Last Decade

Srikanth Ambati

49 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srikanth Ambati United States 13 277 172 151 98 95 62 538
Tiziana Megha Italy 14 263 0.9× 268 1.6× 125 0.8× 79 0.8× 98 1.0× 28 561
Thomas Boulet France 17 352 1.3× 58 0.3× 206 1.4× 138 1.4× 127 1.3× 36 686
Carlos Barranco Spain 16 174 0.6× 103 0.6× 273 1.8× 59 0.6× 179 1.9× 40 793
Cynthia Helsabeck United States 11 224 0.8× 127 0.7× 105 0.7× 36 0.4× 51 0.5× 15 553
Matthew D. Stachler United States 15 320 1.2× 84 0.5× 344 2.3× 90 0.9× 293 3.1× 38 911
Ayse U. Akarca United Kingdom 14 475 1.7× 196 1.1× 183 1.2× 53 0.5× 89 0.9× 34 773
Leo M. Budel Netherlands 13 332 1.2× 242 1.4× 201 1.3× 30 0.3× 108 1.1× 24 780
Jan‐Henrik Mikesch Germany 15 212 0.8× 42 0.2× 330 2.2× 35 0.4× 85 0.9× 54 680
Salim Yazji United States 12 303 1.1× 186 1.1× 220 1.5× 39 0.4× 155 1.6× 29 738
Lorena Baboçi Italy 18 260 0.9× 53 0.3× 215 1.4× 26 0.3× 87 0.9× 27 811

Countries citing papers authored by Srikanth Ambati

Since Specialization
Citations

This map shows the geographic impact of Srikanth Ambati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srikanth Ambati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srikanth Ambati more than expected).

Fields of papers citing papers by Srikanth Ambati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srikanth Ambati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srikanth Ambati. The network helps show where Srikanth Ambati may publish in the future.

Co-authorship network of co-authors of Srikanth Ambati

This figure shows the co-authorship network connecting the top 25 collaborators of Srikanth Ambati. A scholar is included among the top collaborators of Srikanth Ambati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srikanth Ambati. Srikanth Ambati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Arnason, Jon, Matthew J. Matasar, Stefano Luminari, et al.. (2025). Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Advances. 9(23). 6130–6140.
3.
Keudell, Gottfried von, Eliza A. Hawkes, Cecilia Carpio, et al.. (2024). Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab. Blood. 144(Supplement 1). 3080–3080.
4.
Ayyappan, Sabarish, H. Miles Prince, Cecilia Carpio, et al.. (2024). Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study. Blood. 144(Supplement 1). 4486–4486.
5.
Vitolo, Umberto, Michele Merli, Lalita Norasetthada, et al.. (2024). Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).. Journal of Clinical Oncology. 42(16_suppl). TPS7094–TPS7094. 2 indexed citations
6.
Birhiray, Ruemu, Stefano Luminari, Tae Min Kim, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).. Journal of Clinical Oncology. 42(16_suppl). TPS7096–TPS7096. 2 indexed citations
7.
8.
Brouwer‐Visser, Jurriaan, Nathalie Fiaschi, Raquel P. Deering, et al.. (2024). Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 12(3). e008338–e008338. 13 indexed citations
9.
Hawkes, Eliza A., Geoffrey Chong, Dina M. Flink, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).. Journal of Clinical Oncology. 42(16_suppl). TPS7093–TPS7093. 2 indexed citations
10.
Gray, Carl, Silvana Novelli, Tuba Hacıbekiroğlu, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).. Journal of Clinical Oncology. 42(16_suppl). TPS7099–TPS7099. 4 indexed citations
11.
12.
Poon, Michelle, Jan Walewski, Isidro Jarque, et al.. (2023). ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2. Hematological Oncology. 41(S2). 141–142. 5 indexed citations
13.
Jalbert, Jessica J., Ning Wu, Chieh-I Chen, et al.. (2022). Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma. Advances in Therapy. 39(6). 2630–2640. 5 indexed citations
14.
Marturano-Kruik, Alessandro, Aránzazu Villasante, Srikanth Ambati, et al.. (2017). Biomechanical regulation of drug sensitivity in an engineered model of human tumor. Biomaterials. 150. 150–161. 45 indexed citations
15.
Mathias, Melissa, Michael V. Ortiz, Heather Magnan, et al.. (2017). A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition. Biomarker Research. 5(1). 7–7. 1 indexed citations
16.
Villasante, Aránzazu, Alessandro Marturano-Kruik, Srikanth Ambati, et al.. (2016). Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics. 6(8). 1119–1130. 75 indexed citations
17.
Pera, Benet, M. Nieves Calvo-Vidal, Srikanth Ambati, et al.. (2015). High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. Cancer Letters. 368(1). 97–104. 10 indexed citations
18.
Gupta, Vineeta, et al.. (2008). Superior vena cava syndrome in children. Indian Journal of Hematology and Blood Transfusion. 24(1). 28–30. 14 indexed citations
19.
Ambati, Srikanth, et al.. (2008). Rosai–Dorfman disease following bone marrow transplantation for pre‐B cell acute lymphoblastic leukemia. Pediatric Blood & Cancer. 51(3). 433–435. 15 indexed citations
20.
Ambati, Srikanth, et al.. (2007). Diagnosis of typhoid fever by polymerase chain reaction. The Indian Journal of Pediatrics. 74(10). 909–913. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tiziana Megha Breakdown of academic impact, for papers by Thomas Boulet Breakdown of academic impact, for papers by Carlos Barranco Breakdown of academic impact, for papers by Cynthia Helsabeck Breakdown of academic impact, for papers by Matthew D. Stachler Breakdown of academic impact, for papers by Ayse U. Akarca Breakdown of academic impact, for papers by Leo M. Budel Breakdown of academic impact, for papers by Jan‐Henrik Mikesch Breakdown of academic impact, for papers by Salim Yazji Breakdown of academic impact, for papers by Lorena Baboçi
Rankless by CCL
2026